IL11 and cancer: For translation into the clinic, future studies on a higher number of tumor models will have to show if this also holds true for combinations with other chemotherapeutic agents, and whether other cytokines such as IL-2 and IL-11 that are already applied for treatment of thrombocytopenia in cancer patients receiving chemotherapy, will be as efficacious or maybe even superior to hyper-IL-6 in reducing thrombocytopenia and improving overall wellbeing in combination with oncolytic viral therapy.